Second-generation epothilones: Discovery of fludelone and its extraordinary antitumor properties

Drugs of the Future

Volumn 30, Issue 7, 2005, Pages 737-745

  Cho, Young Shin ^a   Wu, Kai Da ^a   Moore, Malcolm A S ^a   Chou, Ting Chao ^a   Danishefsky, Samuel J ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Havemeyer Hall ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

12,13 DESOXY EPOTHILONE B; 9,10 DEHYDRO EPOTHILONE B; EPOTHILONE A; EPOTHILONE B; EPOTHILONE DERIVATIVE; FLUDELONE; PACLITAXEL; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE; CELL GROWTH; COLON CARCINOMA; CYTOTOXICITY; DRUG BINDING; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; GROWTH INHIBITION; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; LYMPHATIC LEUKEMIA; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION; TOXICITY TESTING; WEIGHT REDUCTION;

EID: 27644559079     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2005.030.07.895806     Document Type: Review

References (31)

1. Nicolaou, K.C., Sorensen, E.J. Classics in Total Synthesis: Targets, Strategies, Methods. VCH Publishers, Inc.: Weinheim, New York 1996.
2. Nicolaou, K.C., Snyder, S. Classics in Total Synthesis II: More Targets, Strategies, Methods. VCH Publishers, Inc.: Weinheim, New York 2003.
3. Danishefsky, S.J. Observations on the state of synthesis: Some magic moments revisited. Tetrahedron 1997, 53: 8689.
4. Njardarson, J.T., Gaul, C., Shan, D., Huang, X.-Y., Danishefsky, S.J. Discovery of potent cell migration inhibitors through total synthesis: Lessons from structure-activity studies of (+)-migrastatin. J Am Chem Soc 2004, 126: 1038-40.
5. Ravelo, A.G., Estevez-Braun, A., Chavez-Orellana, H., Perez-Sacau, E., Mesa-Siverio, D. Recent studies on natural products as anticancer agents. Curr Top Med Chem 2004, 4: 241-65, and references therein.
6. Towle, M.J., Salvato, K.A., Budrow, J. et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res 2001, 61: 1013-21.
7. Martinez, E.J., Corey, E.J., Owa, T. Antitumor activity- and gene expression-based profiling of ecteinascidin (Et 743) and phthalascidin (Pt 650). Chem Biol 2001, 8: 1151-60.
8. Höfle, G., Bedorf, N., Gerth, K., Reichenbach, H. DE-B 4138042. Chem Abstr 1993, 120: 52841.
9. Bollag, D.M., McQueney, P.A., Zgu, J. et al. Epothilones, a new class of microtubule-stabilizing agents with a Taxol-like mechanism of action. Cancer Res 1995, 55: 2325-33.
10. Kowalski, R.J., Terhaar, E., Longley, R.E. et al. Comparison of novel microtubule polymerizing agents, discodermolide and epothilone A/B, with Taxol. Mol Biol Cell 1995, 6: 2137-2137.
11. Rowinsky, E.K., Eisenhauer, E.A., Chaudhry, V., Arbuck, S.G., Donehower, R.C. Clinical toxicities encountered with paclitaxel. Semin Oncol 1993, 20: 1-15.
12. Fletcher, B.S., Kujubu, D.A., Perrin, D.M., Herschman, H.R. Structure of the mitogen-inducible TIS10 gene and demonstration that the TIS10-encoded protein is a functional prostaglandin G/H synthase. J Biol Chem 1992, 267: 4338-44.
13. Tsuji, M., Dubois, R.N. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995, 3: 493-501.
14. Essayan, D.M., Kagey-Sobotka, A., Colarusso, P.J., Lichtenstein, L.M., Ozols, R.F., King, E.D. Successful parenteral desensitization to paclitaxel. J Allergy Clin Immunol I 1996, 97: 42-6.
15. Giannakakou, P., Sackett, D.L., Kang, Y.-K. et al. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 1997, 272: 17118-25, and references therein.
16. Balog, A., Meng, D.F., Kamenecka, T. et al. Total synthesis of (-)-epothilone A. Angew Chem Int Ed 1996, 35: 2801-3.
17. Chou, T.C., Zhang, X.G., Balog, A. et al. Desoxyepothilone B: An efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B. Proc Natl Acad Sci USA 1998, 95: 9642-7.
18. Chou, T.C., Zhang, X.G., Harris, C.R. et al. Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel. Proc Natl Acad Sci USA 1998, 95: 15798-802.
19. Meng, D.F., Bertinato, P., Balog, A. et al. The total syntheses of epothilones A and B. J Am Chem Soc 1997, 119: 10073-92.
20. Chou, T.C., O'Connor, O.A., long, W.P. et al. The synthesis, discovery, and development of a highly promising class of microtubule stabilization agents: Curative effects of desoxyepothilones B and F against human tumor xenografts in nude mice. Proc Natl Acad Sci USA 2001, 98: 8113-8.
21. For more information about clinical trials of dEpoB, visit: www.kosan.com.
22. Rivkin, A., Yoshimura, F., Gabarda, A.E. et al. Discovery of (E)-9,10-dehydroepothilones through chemical synthesis: On the emergence of 26-trifluoro-(E)-9,10-dehydro-12,13-desoxyepothilone B as a promising anticancer drug candidate. J Am Chem Soc 2004, 126: 10913-22.
23. Rivkin, A., Yoshimura, F., Gabarda, A.E. et al. Complex target-oriented total synthesis in the drug discovery process: The discovery of a family of second generation epothilone drug candidates. J Am Chem Soc 2003, 125: 2899-901.
24. Chou, T.-C., Dong, H., Rivkin, A. et al. Design and total synthesis of a superior family of epothilone analogs, which eliminate xenograft tumors to a nonrelapsable state. Angew Chem Int Ed 2003, 42: 4761-7.
25. Yoshimura, F., Rivkin, A., Gabarda, A.E. et al. Synthesis and conformational analysis of (E)-9,10-dehydroepothilone B: A suggestive link between the chemistry and biology of epothilones. Angew Chem Int Ed 2003, 42: 2518-21.
26. Altmann, K.H., Bolds, G., Caravatti, G., Flörsheimer, A., Guagnano, V., Wartmann, M. Synthesis and biological evaluation of highly potent analogues of epothilones B and D. Bioorg Med Chem Lett 2000, 10: 2765-8.
27. Nicolaou, K.C., Scarpelli, R., Bollbuck, B. et al. Chemical synthesis and biological properties of pyridine epothilones. Chem Biol 2000, 7: 593-9.
28. Miller, H.J., Leong, T., Khandekar, J.D., Greipp, P.R., Gertz, M.A., Kyle, R.A. Paclitaxel as the initial treatment of multiple myeloma - an Eastern Cooperative Oncology Group Study (E1A93). Am J Clin Oncol 1998, 21: 553-6.
29. Jazirehi, A.R., Bonavida, B. Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkins lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther 2004, 3: 71-84.
30. Tjuvajev, J.G., Blasberg, R.G. In vivo imaging of moleculargenetic targets for cancer therapy. Cancer Cell 2003, 3: 327-32.
31. Wu, K.-D., Cho, Y.-S., Katz, J., Ponomarev, V., Chen-Kiang, S., Danishefsky, S.J., Moore, M.A.S. Investigation of antitumor effects of synthetic epothilone analogs in human myeloma models in vitro and in vivo. Proc Natl Acad Sci USA 2005, 102: 10640-5.